Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences Ltd ( (AU:ANR) ) has shared an update.
Anatara Lifesciences reported that interim pre-clinical data from its Anti-Obesity Project at the University of Newcastle identified a lead candidate compound, AOC, which showed statistically significant effects in attenuating post-semaglutide weight regain and reducing visceral (perigonadal) fat in a mouse model of diet-induced obesity, supporting its potential as an oral complementary therapy to help maintain weight loss after GLP-1 treatments. Completion of detailed mechanism-of-action studies has been delayed by international supply issues with a key testing kit, with results now expected in February 2026, after which Anatara will decide on further development and commercialisation steps; during the quarter the company also completed a $1.2 million capital raise, ended with $1.035 million in cash, advanced publication-ready analysis of its GaRP gastrointestinal health program, and signalled its intention to continue evaluating strategic opportunities across the junior healthcare sector while maintaining tight financial control.
The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd (ASX: ANR) is an Adelaide-based developer of evidence-based, innovative health products targeting significant unmet needs in human health, with current focus areas including anti-obesity therapeutics and gastrointestinal health. The company operates within the junior healthcare and biotech sector, advancing proprietary drug candidates and complementary medicines aimed at supporting weight management and improving gastrointestinal outcomes, while reviewing additional opportunities and assets to broaden its project portfolio.
Average Trading Volume: 663,113
Technical Sentiment Signal: Sell
Current Market Cap: A$4.39M
For a thorough assessment of ANR stock, go to TipRanks’ Stock Analysis page.